ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Inflammation biomarkers and Alzheimer's disease: A pilot study using NULISAseq.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Dissecting Alzheimer's proteomic landscape through NULISA profiling of brain cell-specific extracellular vesicles.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Biomarker Based ARIA Stress Test: A Proposed Conceptual Framework for Dynamic Biomarker-Guided ARIA Risk Stratification in Anti-Amyloid Immunotherapy for Alzheimer's Disease.Journal of molecular neuroscience : MN · 2026Review
- Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.Alzheimer's research & therapy · 2026Article
- Evaluation of serum as an alternative matrix to plasma for NULISA‑based proteomic blood biomarker measurements.Scientific reports · 2026Article
- Long-COVID: assessment of circulating markers suggests no cerebral neuronal damage, neuroinflammation or systemic inflammation-a controlled study.Scientific reports · 2026Article
- Low-grade, systemic inflammation and the risk of perioperative neurocognitive disorders in an observational study of older adults.Scientific reports · 2025Observational
- Comparison of three multiplex immunoassays for biomarker analysis in stratum corneum tape strips.Scientific reports · 2025Article
- Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform.medRxiv : the preprint server for health sciences · 2025Article
- Plasma proteomic signatures of preclinical Alzheimer's disease biomarkers and memory in clinically unimpaired older adults.medRxiv : the preprint server for health sciences · 2025Article
- Inflammation biomarkers and Alzheimer's disease: A pilot study using NULISAseq.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionIncreasing evidence links amyloid beta (Aβ) aggregation with inflammation. This pilot study investigated the use of an immunoassay panel to map biomarker changes in patients with Alzheimer's disease (AD). Furthermore, we evaluated the stability of protein quantification after multiple freeze-thaw cycles (FTCs).
methodsThe nucleic acid-linked immuno-sandwich assay (NULISA) inflammation panel measured 203 proteins in serum samples of individuals with (
resultsAfter multiple-testing adjustments, glial fibrillary acidic protein ( DISCUSSION: Monitoring of inflammation in AD, using the 200-plex NULISA panel, demonstrates changes in peripherally circulating inflammation-related proteins. Contrary to previous reports, FTCs had minimal impact on the quantification of inflammatory markers. Highlights: The novel nucleic acid-linked immuno-sandwich assay (NULISA) inflammation panel, which includes 200 protein biomarkers, was used.The panel was used for the first time in serum from patients with Alzheimer's disease (AD).The protein S100A12 was identified as a potential biomarker for AD.Inflammation markers were stable in up to five freeze-thaw cycles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.